IntraBio has been dedicated to bringing novel treatments to patients with extremely high unmet medical needs like NPC, and today we celebrate a major milestone in this tremendous effort https://t.co/xWLKJRGPS2
IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease)
https://t.co/I42rifjHeW
IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C https://t.co/xyunE4eO6H
JOIN US THIS MORNING for the NNPDF Industry webinar series as @IntraBio presents at 11:00 am ET/8:00 am PT. Hear updates regarding their Clinical Trial IB1001-201 and more! REGISTER NOW at: https://t.co/DEbdE5Ybh6
#NPC#niemannpick#nnpdf
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Ataxia-Telangiectasia #RareDisease#IntraBio#Ataxia#FDA#Biotech
https://t.co/0J6RS9SnQT
IntraBio Clinical Trial Authorisation Application Approved by the MHRA for the treatment of Niemann-Pick Disease Type C #RareDisease#IntraBio#MHRA#NPC
https://t.co/pR2UpHyTL6
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Niemann-Pick Disease Type C #RareDisease#Biotech#FDA#IntraBio#IND
https://t.co/WlPfRS0Js5
IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of Tay-Sachs and Sandhoff Disease #RareDisease#Biotech#FDA#IntraBio
https://t.co/LxqIFfsUxr
RareDaily reports on our recent Rare Pediatric Disease Designation for Niemann-Pick disease Type C for our lead compound series
https://t.co/X7paklrYQ6 via @GlobalGenes
IntraBio is pleased to announce that its lead drug series IB1000s has been granted Orphan Medicinal Drug Designation by the European Commission for the treatment of Spinocerebellar Ataxia #RareDisease#Ataxia#IntraBio
https://t.co/LQhKlmqhuZ